Tags

Type your tag names separated by a space and hit enter

Does cannabidiol have a role in the treatment of schizophrenia?
Schizophr Res. 2016 10; 176(2-3):281-290.SR

Abstract

Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and society-at-large. Unfortunately, currently available therapeutic strategies do not provide adequate relief and some patients are treatment-resistant. In this regard, cannabidiol (CBD), a non-psychoactive constituent of Cannabis sativa, has shown significant promise as a potential antipsychotic for the treatment of schizophrenia. However, there is still considerable uncertainty about the mechanism of action of CBD as well as the brain regions which are thought to mediate its putative antipsychotic effects. We argue that further research on CBD is required to fast-track its progress to the clinic and in doing so, we may generate novel insights into the neurobiology of schizophrenia.

Authors+Show Affiliations

Department of Anatomy & Neuroscience, University College Cork, Cork, Ireland. Electronic address: anand.gururajan@ucc.ie.Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy & Pharmaceutical Sciences, Monash University, Melbourne, Australia.

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27374322

Citation

Gururajan, Anand, and Daniel Thomas Malone. "Does Cannabidiol Have a Role in the Treatment of Schizophrenia?" Schizophrenia Research, vol. 176, no. 2-3, 2016, pp. 281-290.
Gururajan A, Malone DT. Does cannabidiol have a role in the treatment of schizophrenia? Schizophr Res. 2016;176(2-3):281-290.
Gururajan, A., & Malone, D. T. (2016). Does cannabidiol have a role in the treatment of schizophrenia? Schizophrenia Research, 176(2-3), 281-290. https://doi.org/10.1016/j.schres.2016.06.022
Gururajan A, Malone DT. Does Cannabidiol Have a Role in the Treatment of Schizophrenia. Schizophr Res. 2016;176(2-3):281-290. PubMed PMID: 27374322.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Does cannabidiol have a role in the treatment of schizophrenia? AU - Gururajan,Anand, AU - Malone,Daniel Thomas, Y1 - 2016/07/01/ PY - 2015/10/23/received PY - 2016/06/15/revised PY - 2016/06/17/accepted PY - 2016/7/5/entrez PY - 2016/7/5/pubmed PY - 2018/1/3/medline KW - Antipsychotic KW - Cannabidiol KW - Schizophrenia SP - 281 EP - 290 JF - Schizophrenia research JO - Schizophr Res VL - 176 IS - 2-3 N2 - Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and society-at-large. Unfortunately, currently available therapeutic strategies do not provide adequate relief and some patients are treatment-resistant. In this regard, cannabidiol (CBD), a non-psychoactive constituent of Cannabis sativa, has shown significant promise as a potential antipsychotic for the treatment of schizophrenia. However, there is still considerable uncertainty about the mechanism of action of CBD as well as the brain regions which are thought to mediate its putative antipsychotic effects. We argue that further research on CBD is required to fast-track its progress to the clinic and in doing so, we may generate novel insights into the neurobiology of schizophrenia. SN - 1573-2509 UR - https://www.unboundmedicine.com/medline/citation/27374322/Does_cannabidiol_have_a_role_in_the_treatment_of_schizophrenia L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920-9964(16)30289-4 DB - PRIME DP - Unbound Medicine ER -